Cann Group (CAN) Stock Overview

Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. More details

CAN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	0/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (0.4x) is below the Australian market (17x)

Became profitable this year

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the Australian market

Does not have a meaningful market cap (A$8M)

Debt is not well covered by operating cash flow

+ 1 more risk

CAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW439,757 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

439,757 investors already sharing narratives

View all narratives

Cann Group Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cann Group
Historical stock prices
Current Share Price	AU$0.005
52 Week High	AU$0.023
52 Week Low	AU$0.002
Beta	0.11
1 Month Change	66.67%
3 Month Change	25.00%
1 Year Change	-54.55%
3 Year Change	-96.00%
5 Year Change	-98.21%
Change since IPO	-99.22%

Recent updates

Analysis Article • Jul 20

Cann Group Limited's (ASX:CAN) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

Cann Group Limited ( ASX:CAN ) shareholders are no doubt pleased to see that the share price has bounced 36% in the...

Analysis Article • Jun 02

Investors Aren't Buying Cann Group Limited's (ASX:CAN) Revenues

Cann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy right now...

Analysis Article • Jan 31

The Market Doesn't Like What It Sees From Cann Group Limited's (ASX:CAN) Revenues Yet

Cann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...

Analysis Article • Sep 24

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Despite an already strong run, Cann Group Limited ( ASX:CAN ) shares have been powering on, with a gain of 36% in the...

Analysis Article • Jun 04

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

With a price-to-sales (or "P/S") ratio of 1x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at the...

Analysis Article • Dec 27

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

With a price-to-sales (or "P/S") ratio of 2.2x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at...

Analysis Article • May 18

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Analysis Article • Nov 03

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

The underwhelming share price performance of Cann Group Limited ( ASX:CAN ) in the past three years would have...

Analysis Article • Feb 23

Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Nov 25

What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Cann Group Limited (ASX:CAN) shareholders will doubtless be very grateful to see the share price up 77% in the last...

Analysis Article • Nov 25

One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be

Market forces rained on the parade of Cann Group Limited (ASX:CAN) shareholders today, when the covering analyst...

Shareholder Returns

	CAN	AU Pharmaceuticals	AU Market
7D	0%	-1.8%	-2.9%
1Y	-54.5%	-7.4%	-2.6%

Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -7.4% over the past year.

Return vs Market: CAN underperformed the Australian Market which returned -2.6% over the past year.

Price Volatility

Is CAN's price volatile compared to industry and market?
CAN volatility
CAN Average Weekly Movement	48.3%
Pharmaceuticals Industry Average Movement	10.9%
Market Average Movement	9.7%
10% most volatile stocks in AU Market	16.7%
10% least volatile stocks in AU Market	4.0%

Stable Share Price: CAN's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: CAN's weekly volatility has increased from 31% to 48% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	n/a	www.canngrouplimited.com

Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.

Cann Group Limited Fundamentals Summary

How do Cann Group's earnings and revenue compare to its market cap?
CAN fundamental statistics
Market cap	AU$8.30m
Earnings (TTM)	AU$20.30m
Revenue (TTM)	AU$9.65m

0.4x

P/E Ratio

0.9x

P/S Ratio

Is CAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAN income statement (TTM)
Revenue	AU$9.65m
Cost of Revenue	AU$3.66m
Gross Profit	AU$5.99m
Other Expenses	-AU$14.31m
Earnings	AU$20.30m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	0.012
Gross Margin	62.09%
Net Profit Margin	210.36%
Debt/Equity Ratio	56.3%

How did CAN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/12 20:19
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2026/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cann Group Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Cameron Bell	Canaccord Genuity
Paul Jensz	PAC Partners Securities Pty. Ltd.

Cann Group (CAN) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Cann Group Limited Competitors

Epsilon Healthcare

Little Green Pharma

Medical Developments International

Vita Life Sciences

Price History & Performance

Recent News & Updates

Full year 2026 earnings released: EPS: AU$0.016 (vs AU$0.042 loss in FY 2025)

New major risk - Financial position

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.

Cann Group Limited, Annual General Meeting, Nov 28, 2025

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)

Recent updates

Full year 2026 earnings released: EPS: AU$0.016 (vs AU$0.042 loss in FY 2025)

New major risk - Financial position

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.

Cann Group Limited, Annual General Meeting, Nov 28, 2025

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)

New major risk - Share price stability

New major risk - Financial position

Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)

Cann Group Limited's (ASX:CAN) Share Price Boosted 36% But Its Business Prospects Need A Lift Too

Cann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract Renewed

Investors Aren't Buying Cann Group Limited's (ASX:CAN) Revenues

New minor risk - Share price stability

New major risk - Shareholder dilution

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.

New minor risk - Financial data availability

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.

New major risk - Market cap size

The Market Doesn't Like What It Sees From Cann Group Limited's (ASX:CAN) Revenues Yet

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

Cann Group (ASX:CAN) Is Making Moderate Use Of Debt

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now

Chief Financial Officer Greg Bullock has left the company